{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T16:24:39Z","timestamp":1780590279857,"version":"3.54.1"},"reference-count":293,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T00:00:00Z","timestamp":1620691200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01NS076991-01"],"award-info":[{"award-number":["R01NS076991-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P01HL131471-02"],"award-info":[{"award-number":["P01HL131471-02"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UG3HL147367-01"],"award-info":[{"award-number":["UG3HL147367-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01HL097088"],"award-info":[{"award-number":["R01HL097088"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["U19 AI149646-01"],"award-info":[{"award-number":["U19 AI149646-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Conventional vaccinations and immunotherapies have encountered major roadblocks in preventing infectious diseases like HIV, influenza, and malaria. These challenges are due to the high genomic variation and immunomodulatory mechanisms inherent to these diseases. Passive transfer of broadly neutralizing antibodies may offer partial protection, but these treatments require repeated dosing. Some recombinant viral vectors, such as those based on lentiviruses and adeno-associated viruses (AAVs), can confer long-term transgene expression in the host after a single dose. Particularly, recombinant (r)AAVs have emerged as favorable vectors, given their high <jats:italic>in vivo<\/jats:italic> transduction efficiency, proven clinical efficacy, and low immunogenicity profiles. Hence, rAAVs are being explored to deliver recombinant antibodies to confer immunity against infections or to diminish the severity of disease. When used as a vaccination vector for the delivery of antigens, rAAVs enable <jats:italic>de novo<\/jats:italic> synthesis of foreign proteins with the conformation and topology that resemble those of natural pathogens. However, technical hurdles like pre-existing immunity to the rAAV capsid and production of anti-drug antibodies can reduce the efficacy of rAAV-vectored immunotherapies. This review summarizes rAAV-based prophylactic and therapeutic strategies developed against infectious diseases that are currently being tested in pre-clinical and clinical studies. Technical challenges and potential solutions will also be discussed.<\/jats:p>","DOI":"10.3389\/fimmu.2021.673699","type":"journal-article","created":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T06:38:32Z","timestamp":1620715112000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":32,"title":["Vectored Immunotherapeutics for Infectious Diseases: Can rAAVs Be The Game Changers for Fighting Transmissible Pathogens?"],"prefix":"10.3389","volume":"12","author":[{"given":"Wei","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish","family":"Muhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip W. L.","family":"Tai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangping","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,5,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1038\/s41577-020-00479-7","article-title":"A Guide to Vaccinology: From Basic Principles to New Developments","volume":"21","author":"Pollard","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.01963","article-title":"New Vaccine Technologies to Combat Outbreak Situations","volume":"9","author":"Rauch","year":"2018","journal-title":"Front Immunol"},{"key":"B3","article-title":"Analysis of Heterogeneous Viral Populations by Direct DNA Sequencing","volume":"15","author":"Leitner","year":"1993","journal-title":"Biotechniques"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/0042-6822(92)90685-I","article-title":"HIV-1 Genomic RNA Diversification Following Sexual and Parenteral Virus Transmission","volume":"189","author":"Wolfs","year":"1992","journal-title":"Virology"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60164-1","article-title":"HIV Infection: Epidemiology, Pathogenesis, Treatment, and Prevention","volume":"384","author":"Maartens","year":"2014","journal-title":"Lancet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3524","article-title":"Filovirus Pathogenesis and Immune Evasion: Insights From Ebola Virus and Marburg Virus","volume":"13","author":"Messaoudi","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01258-3","article-title":"Ibalizumab: A Review in Multidrug-Resistant Hiv-1 Infection","volume":"80","author":"Blair","year":"2020","journal-title":"Drugs"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12929-019-0592-z","article-title":"Development of Therapeutic Antibodies for the Treatment of Diseases","volume":"27","author":"Lu","year":"2020","journal-title":"J BioMed Sci"},{"key":"B9","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/s41541-017-0019-3","article-title":"Antibody Therapies for the Prevention and Treatment of Viral Infections","volume":"2","author":"Salazar","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B10","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"Sars-CoV-2 Vaccines Strategies: A Comprehensive Review of Phase 3 Candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1080\/21655979.2016.1191707","article-title":"Recent Advances in the Production of Recombinant Subunit Vaccines in Pichia Pastoris","volume":"7","author":"Wang","year":"2016","journal-title":"Bioengineered"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-020-00789-5","article-title":"Antibody-Dependent Enhancement and SARS-CoV-2 Vaccines and Therapies","volume":"5","author":"Lee","year":"2020","journal-title":"Nat Microbiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 Mrna Covid-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the Mrna-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40824-019-0156-z","article-title":"Recent Advances in the Development of Gene Delivery Systems","volume":"23","author":"Sung","year":"2019","journal-title":"Biomater Res"},{"key":"B16","doi-asserted-by":"publisher","first-page":"25611","DOI":"10.1038\/srep25611","article-title":"A Retroviral Crispr-Cas9 System for Cellular Autism-Associated Phenotype Discovery in Developing Neurons","volume":"6","author":"Williams","year":"2016","journal-title":"Sci Rep"},{"key":"B17","doi-asserted-by":"publisher","first-page":"16057","DOI":"10.1038\/mtm.2016.57","article-title":"Sendai Virus, an RNA Virus With No Risk of Genomic Integration, Delivers CRISPR\/Cas9 for Efficient Gene Editing","volume":"3","author":"Park","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B18","doi-asserted-by":"publisher","first-page":"e0179514","DOI":"10.1371\/journal.pone.0179514","article-title":"Baculoviral Delivery of CRISPR\/Cas9 Facilitates Efficient Genome Editing in Human Cells","volume":"12","author":"Hindriksen","year":"2017","journal-title":"PloS One"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00298-16","article-title":"Multivalent and Multipathogen Viral Vector Vaccines","volume":"24","author":"Lauer","year":"2017","journal-title":"Clin Vaccine Immunol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-61779-095-9_1","article-title":"Introduction to Viral Vectors","volume":"737","author":"Warnock","year":"2011","journal-title":"Methods Mol Biol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.07.013","article-title":"Adenoviruses as Vaccine Vectors","volume":"10","author":"Tatsis","year":"2004","journal-title":"Mol Ther"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21103643","article-title":"High-Capacity Adenoviral Vectors: Expanding the Scope of Gene Therapy","volume":"21","author":"Ricobaraza","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1038\/s41392-021-00487-6","article-title":"Viral Vector Platforms Within the Gene Therapy Landscape","volume":"6","author":"Bulcha","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)31605-6","article-title":"Immunogenicity and Safety of a Recombinant Adenovirus Type-5-Vectored COVID-19 Vaccine in Healthy Adults Aged 18 Years or Older: A Randomised, Double-Blind, Placebo-Controlled, Phase 2 Trial","volume":"396","author":"Zhu","year":"2020","journal-title":"Lancet"},{"key":"B25","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and Efficacy of the ChAdOx1 nCoV-19 Vaccine (AZD1222) Against SARS-CoV-2: An Interim Analysis of Four Randomised Controlled Trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim Results of a Phase 1-2a Trial of Ad26.COV2.S Covid-19 Vaccine","author":"Sadoff","year":"2021","journal-title":"N\u00a0Engl J Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.gendis.2017.04.001","article-title":"Adenovirus-Mediated Gene Delivery: Potential Applications for Gene and Cell-Based Therapies in the New Era of Personalized Medicine","volume":"4","author":"Lee","year":"2017","journal-title":"Genes Dis"},{"key":"B28","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.virol.2008.04.016","article-title":"Genetic Delivery of an anti-RSV Antibody to Protect Against Pulmonary Infection With RSV","volume":"378","author":"Skaricic","year":"2008","journal-title":"Virology"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.021","article-title":"Passive Immunization With a Recombinant Adenovirus Expressing an HA (H5)-Specific Single-Domain Antibody Protects Mice From Lethal Influenza Infection","volume":"97","author":"Tutykhina","year":"2013","journal-title":"Antiviral Res"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300344","article-title":"Rapid\/Sustained Anti-Anthrax Passive Immunity Mediated by Co-Administration of Ad\/AAV","volume":"16","author":"De","year":"2008","journal-title":"Mol Ther"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61591-3","article-title":"Efficacy Assessment of a Cell-Mediated Immunity HIV-1 Vaccine (the Step Study): A Double-Blind, Randomised, Placebo-Controlled, Test-of-Concept Trial","volume":"372","author":"Buchbinder","year":"2008","journal-title":"Lancet"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61592-5","article-title":"HIV-1 Vaccine-Induced Immunity in the Test-of-Concept Step Study: A Case-Cohort Analysis","volume":"372","author":"McElrath","year":"2008","journal-title":"Lancet"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1310566","article-title":"Efficacy Trial of a DNA\/rAd5 HIV-1 Preventive Vaccine","volume":"369","author":"Hammer","year":"2013","journal-title":"N Engl J Med"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8463-8471.1998","article-title":"A Third-Generation Lentivirus Vector With a Conditional Packaging System","volume":"72","author":"Dull","year":"1998","journal-title":"J Virol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.272.5259.263","article-title":"In Vivo Gene Delivery and Stable Transduction of Nondividing Cells by a Lentiviral Vector","volume":"272","author":"Naldini","year":"1996","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1089\/104303401753153947","article-title":"Systematic Determination of the Packaging Limit of Lentiviral Vectors","volume":"12","author":"Kumar","year":"2001","journal-title":"Hum Gene Ther"},{"key":"B37","doi-asserted-by":"publisher","first-page":"818","DOI":"10.1038\/nrd.2017.249","article-title":"Second Anticancer CAR T Therapy Receives FDA Approval","volume":"16","author":"Mullard","year":"2017","journal-title":"Nat Rev Drug Discovery"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1038\/s41576-019-0205-4","article-title":"Engineering Adeno-Associated Virus Vectors for Gene Therapy","volume":"21","author":"Li","year":"2020","journal-title":"Nat Rev Genet"},{"key":"B39","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1111\/j.1538-7836.2006.02220.x","article-title":"Efficacy and Safety of Adeno-Associated Viral Vectors Based on Serotype 8 and 9 vs. Lentiviral Vectors for Hemophilia B Gene Therapy","volume":"5","author":"Vandendriessche","year":"2007","journal-title":"J\u00a0Thromb Haemost"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1006\/mcne.2002.1168","article-title":"Intravitreal Injection of Adeno-Associated Viral Vectors Results in the Transduction of Different Types of Retinal Neurons in Neonatal and Adult Rats: A Comparison With Lentiviral Vectors","volume":"21","author":"Harvey","year":"2002","journal-title":"Mol Cell Neurosci"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1517\/17425247.2015.966682","article-title":"Gene Therapy for Neurologic Manifestations of Mucopolysaccharidoses","volume":"12","author":"Wolf","year":"2015","journal-title":"Expert Opin Drug Delivery"},{"key":"B42","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1089\/hgtb.2017.084","article-title":"Pseudotyped Lentiviral Vectors: One Vector, Many Guises","volume":"28","author":"Joglekar","year":"2017","journal-title":"Hum Gene Ther Methods"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2017.04.002","article-title":"Integrase-Deficient Lentiviral Vector as an All-in-One Platform for Highly Efficient CRISPR\/Cas9-Mediated Gene Editing","volume":"5","author":"Ortinski","year":"2017","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201303374","article-title":"Targeted Gene Therapy and Cell Reprogramming in Fanconi Anemia","volume":"6","author":"Rio","year":"2014","journal-title":"EMBO Mol Med"},{"key":"B45","doi-asserted-by":"publisher","first-page":"e01911","DOI":"10.7554\/eLife.01911","article-title":"Targeted Genome Editing by Lentiviral Protein Transduction of Zinc-Finger and TAL-effector Nucleases","volume":"3","author":"Cai","year":"2014","journal-title":"Elife"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2016.27","article-title":"Lentivirus Pre-Packed With Cas9 Protein for Safer Gene Editing","volume":"23","author":"Choi","year":"2016","journal-title":"Gene Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"86","DOI":"10.2174\/1566523214666140302193709","article-title":"Basic Biology of Adeno-Associated Virus (AAV) Vectors Used in Gene Therapy","volume":"14","author":"Balakrishnan","year":"2014","journal-title":"Curr Gene Ther"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41573-019-0012-9","article-title":"Adeno-Associated Virus Vector as a Platform for Gene Therapy Delivery","volume":"18","author":"Wang","year":"2019","journal-title":"Nat Rev Drug Discovery"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaw2900","article-title":"Comprehensive AAV Capsid Fitness Landscape Reveals a Viral Gene and Enables Machine-Guided Design","volume":"366","author":"Ogden","year":"2019","journal-title":"Science"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.6.3495-3504.2003","article-title":"Genetic Fate of Recombinant Adeno-Associated Virus Vector Genomes in Muscle","volume":"77","author":"Schnepp","year":"2003","journal-title":"J Virol"},{"key":"B51","article-title":"Adeno-Associated Virus Vector Integration","volume":"11","author":"Deyle","year":"2009","journal-title":"Curr Opin Mol Ther"},{"key":"B52","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.72.11.8568-8577.1998","article-title":"Circular Intermediates of Recombinant Adeno-Associated Virus Have Defined Structural Characteristics Responsible for Long-Term Episomal Persistence in Muscle Tissue","volume":"72","author":"Duan","year":"1998","journal-title":"J Virol"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2011-09-382317","article-title":"Factor IX Expression in Skeletal Muscle of a Severe Hemophilia B Patient 10 Years After AAV-mediated Gene Transfer","volume":"119","author":"Buchlis","year":"2012","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.23.14793-14803.2005","article-title":"Characterization of Adeno-Associated Virus Genomes Isolated From Human Tissues","volume":"79","author":"Schnepp","year":"2005","journal-title":"J Virol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41587-020-0741-7","article-title":"A Long-Term Study of AAV Gene Therapy in Dogs With Hemophilia A Identifies Clonal Expansions of Transduced Liver Cells","volume":"39","author":"Nguyen","year":"2021","journal-title":"Nat Biotechnol"},{"key":"B56","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/1743-422X-10-74","article-title":"A Survey of Ex Vivo\/In Vitro Transduction Efficiency of Mammalian Primary Cells and Cell Lines With Nine Natural Adeno-Associated Virus (AAV1-9) and One Engineered Adeno-Associated Virus Serotype","volume":"10","author":"Ellis","year":"2013","journal-title":"Virol J"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2010.55","article-title":"Engineering of Human Pluripotent Stem Cells by AAV-mediated Gene Targeting","volume":"18","author":"Khan","year":"2010","journal-title":"Mol Ther"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1038\/s41592-019-0329-7","article-title":"One-Step Generation of Modular CAR-T Cells With AAV-Cpf1","volume":"16","author":"Dai","year":"2019","journal-title":"Nat Methods"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.01.001","article-title":"Immune Responses to Viral Gene Therapy Vectors","volume":"28","author":"Shirley","year":"2020","journal-title":"Mol Ther"},{"key":"B60","doi-asserted-by":"publisher","first-page":"107453","DOI":"10.1016\/j.pharmthera.2019.107453","article-title":"Adeno-Associated Viral Vector-Mediated Immune Responses: Understanding Barriers to Gene Delivery","volume":"207","author":"Nidetz","year":"2020","journal-title":"Pharmacol Ther"},{"key":"B61","doi-asserted-by":"publisher","DOI":"10.1172\/JCI143780","article-title":"Overcoming Innate Immune Barriers That Impede AAV Gene Therapy Vectors","volume":"131","author":"Muhuri","year":"2021","journal-title":"J Clin Invest"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2014.00005","article-title":"Aav Vectors Vaccines Against Infectious Diseases","volume":"5","author":"Nieto","year":"2014","journal-title":"Front Immunol"},{"key":"B63","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.virol.2006.03.049","article-title":"Recombinant Adeno-Associated Virus Expressing the Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus S Protein Elicits Neutralizing Antibodies: Implication for Developing SARS Vaccines","volume":"353","author":"Du","year":"2006","journal-title":"Virology"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1089\/hgtb.2015.040","article-title":"Stability and Compatibility of Recombinant Adeno-Associated Virus Under Conditions Commonly Encountered in Human Gene Therapy Trials","volume":"26","author":"Gruntman","year":"2015","journal-title":"Hum Gene Ther Methods"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.71.10.7960-7962.1997","article-title":"Genetic Immunization With Adeno-Associated Virus Vectors Expressing Herpes Simplex Virus Type 2 Glycoproteins B, and D","volume":"71","author":"Manning","year":"1997","journal-title":"J Virol"},{"key":"B66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1146\/annurev-immunol-051116-052433","article-title":"Signaling by Antibodies: Recent Progress","volume":"35","author":"Bournazos","year":"2017","journal-title":"Annu Rev Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01296","article-title":"Conceptual Approaches to Modulating Antibody Effector Functions and Circulation Half-Life","volume":"10","author":"Saunders","year":"2019","journal-title":"Front Immunol"},{"key":"B68","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1146\/annurev-bioeng-071114-040733","article-title":"Advances in Antibody Design","volume":"17","author":"Tiller","year":"2015","journal-title":"Annu Rev BioMed Eng"},{"key":"B69","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1146\/annurev.immunol.23.021704.115732","article-title":"Antigen-Specific Memory B Cell Development","volume":"23","author":"McHeyzer-Williams","year":"2005","journal-title":"Annu Rev Immunol"},{"key":"B70","doi-asserted-by":"publisher","first-page":"e1005090","DOI":"10.1371\/journal.ppat.1005090","article-title":"Aav-Delivered Antibody Mediates Significant Protective Effects Against SIVmac239 Challenge in the Absence of Neutralizing Activity","volume":"11","author":"Fuchs","year":"2015","journal-title":"PloS Pathog"},{"key":"B71","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.immuni.2019.02.005","article-title":"Adeno-Associated Virus Delivery of Anti-HIV Monoclonal Antibodies can Drive Long-Term Virologic Suppression","volume":"50","author":"Martinez-Navio","year":"2019","journal-title":"Immunity"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2009.255","article-title":"Effect of Genome Size on AAV Vector Packaging","volume":"18","author":"Wu","year":"2010","journal-title":"Mol Ther"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aao4235","article-title":"Protection Against a Mixed SHIV Challenge by a Broadly Neutralizing Antibody Cocktail","volume":"9","author":"Julg","year":"2017","journal-title":"Sci Transl Med"},{"key":"B74","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1038\/s41467-019-13972-y","article-title":"Single-Dose bNAb Cocktail or Abbreviated ART Post-Exposure Regimens Achieve Tight SHIV Control Without Adaptive Immunity","volume":"11","author":"Shapiro","year":"2020","journal-title":"Nat Commun"},{"key":"B75","doi-asserted-by":"publisher","first-page":"16068","DOI":"10.1038\/mtm.2016.68","article-title":"Promise and Problems Associated With the Use of Recombinant AAV for the Delivery of anti-HIV Antibodies","volume":"3","author":"Fuchs","year":"2016","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2020.03.023","article-title":"Crispr-Based Therapeutic Genome Editing: Strategies and In Vivo Delivery by AAV Vectors","volume":"181","author":"Wang","year":"2020","journal-title":"Cell"},{"key":"B77","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1089\/hum.2019.220","article-title":"Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes","volume":"31","author":"Tornabene","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B78","doi-asserted-by":"publisher","first-page":"8360","DOI":"10.1038\/s41598-017-08641-3","article-title":"Efficient Generation of Bispecific IgG Antibodies by Split Intein Mediated Protein Trans-Splicing System","volume":"7","author":"Han","year":"2017","journal-title":"Sci Rep"},{"key":"B79","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3233\/JAD-2011-110230","article-title":"Anti-Amyloid-Beta Single-Chain Antibody Brain Delivery Via Aav Reduces Amyloid Load But May Increase Cerebral Hemorrhages in an Alzheimer\u2019s Disease Mouse Model","volume":"27","author":"Kou","year":"2011","journal-title":"J Alzheimers Dis"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbi.2010.05.010","article-title":"Intramuscular Delivery of a Single Chain Antibody Gene Prevents Brain Abeta Deposition and Cognitive Impairment in a Mouse Model of Alzheimer\u2019s Disease","volume":"24","author":"Wang","year":"2010","journal-title":"Brain Behav Immun"},{"key":"B81","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/mt.2013.239","article-title":"Adeno-Associated Virus-Mediated Delivery of a Recombinant Single-Chain Antibody Against Misfolded Superoxide Dismutase for Treatment of Amyotrophic Lateral Sclerosis","volume":"22","author":"Patel","year":"2014","journal-title":"Mol Ther"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300387","article-title":"CNS Delivery of Vectored Prion-Specific Single-Chain Antibodies Delays Disease Onset","volume":"16","author":"Wuertzer","year":"2008","journal-title":"Mol Ther"},{"key":"B83","doi-asserted-by":"publisher","first-page":"493","DOI":"10.2165\/11531280-000000000-00000","article-title":"Clinical Pharmacokinetics of Therapeutic Monoclonal Antibodies","volume":"49","author":"Keizer","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"B84","doi-asserted-by":"publisher","first-page":"v9","DOI":"10.1093\/ndt\/gfl476","article-title":"Immunogenicity of Biopharmaceuticals","volume":"21","author":"Kessler","year":"2006","journal-title":"Nephrol Dial Transplant"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2016.00021","article-title":"Immunogenicity to Biotherapeutics - The Role of Anti-drug Immune Complexes","volume":"7","author":"Krishna","year":"2016","journal-title":"Front Immunol"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.4161\/mabs.1.2.7909","article-title":"Immunotoxicity of Monoclonal Antibodies","volume":"1","author":"Descotes","year":"2009","journal-title":"MAbs"},{"key":"B87","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1038\/mt.2015.191","article-title":"Host Anti-antibody Responses Following Adeno-Associated Virus-mediated Delivery of Antibodies Against HIV and SIV in Rhesus Monkeys","volume":"24","author":"Martinez-Navio","year":"2016","journal-title":"Mol Ther"},{"key":"B88","doi-asserted-by":"publisher","first-page":"e1007395","DOI":"10.1371\/journal.ppat.1007395","article-title":"Vectored Delivery of anti-SIV Envelope Targeting mAb Via AAV8 Protects Rhesus Macaques From Repeated Limiting Dose Intrarectal Swarm SIVsmE660 Challenge","volume":"14","author":"Welles","year":"2018","journal-title":"PloS Pathog"},{"key":"B89","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30003-7","article-title":"Adeno-Associated Virus Vectored Immunoprophylaxis to Prevent HIV in Healthy Adults: A Phase 1 Randomised Controlled Trial","volume":"6","author":"Priddy","year":"2019","journal-title":"Lancet HIV"},{"key":"B90","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1586\/17474124.2015.1091307","article-title":"The Immunogenicity of Biosimilar Infliximab: can We Extrapolate the Data Across Indications","volume":"9","author":"Ben-Horin","year":"2015","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.76.17.8769-8775.2002","article-title":"Generation of Neutralizing Activity Against Human Immunodeficiency Virus Type 1 in Serum by Antibody Gene Transfer","volume":"76","author":"Lewis","year":"2002","journal-title":"J Virol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/nature10660","article-title":"Antibody-Based Protection Against HIV Infection by Vectored Immunoprophylaxis","volume":"481","author":"Balazs","year":"2011","journal-title":"Nature"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/nm.1967","article-title":"Vector-Mediated Gene Transfer Engenders Long-Lived Neutralizing Activity and Protection Against SIV Infection in Monkeys","volume":"15","author":"Johnson","year":"2009","journal-title":"Nat Med"},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00908-15","article-title":"Broadly Neutralizing Human Immunodeficiency Virus Type 1 Antibody Gene Transfer Protects Nonhuman Primates From Mucosal Simian-Human Immunodeficiency Virus Infection","volume":"89","author":"Saunders","year":"2015","journal-title":"J Virol"},{"key":"B95","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","article-title":"AAV-Expressed eCD4-Ig Provides Durable Protection From Multiple SHIV Challenges","volume":"519","author":"Gardner","year":"2015","journal-title":"Nature"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aau5409","article-title":"AAV-Delivered eCD4-Ig Protects Rhesus Macaques From High-Dose SIVmac239 Challenges","volume":"11","author":"Gardner","year":"2019","journal-title":"Sci Transl Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.1038\/nbt.2618","article-title":"Broad Protection Against Influenza Infection by Vectored Immunoprophylaxis in Mice","volume":"31","author":"Balazs","year":"2013","journal-title":"Nat Biotechnol"},{"key":"B98","doi-asserted-by":"publisher","first-page":"187ra72","DOI":"10.1126\/scitranslmed.3006299","article-title":"Intranasal Antibody Gene Transfer in Mice and Ferrets Elicits Broad Protection Against Pandemic Influenza","volume":"5","author":"Limberis","year":"2013","journal-title":"Sci Transl Med"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00545-13","article-title":"Vectored Expression of the Broadly Neutralizing Antibody FI6 in Mouse Airway Provides Partial Protection Against a New Avian Influenza A Virus, H7N9","volume":"20","author":"Limberis","year":"2013","journal-title":"Clin Vaccine Immunol"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00572-14","article-title":"Adeno-Associated Virus 9-Mediated Airway Expression of Antibody Protects Old and Immunodeficient Mice Against Influenza Virus","volume":"21","author":"Adam","year":"2014","journal-title":"Clin Vaccine Immunol"},{"key":"B101","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1126\/science.aaq0620","article-title":"Universal Protection Against Influenza Infection by a Multidomain Antibody to Influenza Hemagglutinin","volume":"362","author":"Laursen","year":"2018","journal-title":"Science"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00627","article-title":"Protection From Influenza by Intramuscular Gene Vector Delivery of a Broadly Neutralizing Nanobody Does Not Depend on Antibody Dependent Cellular Cytotoxicity","volume":"11","author":"Del Rosario","year":"2020","journal-title":"Front Immunol"},{"key":"B103","doi-asserted-by":"publisher","DOI":"10.1159\/000375262","article-title":"A RIG-I 2card-Mavs200 Chimeric Protein Reconstitutes IFN-Beta Induction and Antiviral Response in Models Deficient in Type I Ifn Response","volume":"7","author":"Nistal-Villan","year":"2015","journal-title":"J Innate Immun"},{"key":"B104","doi-asserted-by":"publisher","first-page":"e10938","DOI":"10.15252\/emmm.201910938","article-title":"Adeno-Associated Virus-Vectored Influenza Vaccine Elicits Neutralizing and Fcgamma Receptor-Activating Antibodies","volume":"12","author":"Demminger","year":"2020","journal-title":"EMBO Mol Med"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.180.2.948","article-title":"Intranasal Vaccination of Recombinant Adeno-Associated Virus Encoding Receptor-Binding Domain of Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Spike Protein Induces Strong Mucosal Immune Responses and Provides Long-Term Protection Against SARS-CoV Infection","volume":"180","author":"Du","year":"2008","journal-title":"J Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2006.09.072","article-title":"AAV Vectors Encoding Malarial Antigens Stimulate Antigen-Specific Immunity But do Not Protect From Parasite Infection","volume":"25","author":"Logan","year":"2007","journal-title":"Vaccine"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1407362111","article-title":"Vectored Antibody Gene Delivery Protects Against Plasmodium Falciparum Sporozoite Challenge in Mice","volume":"111","author":"Deal","year":"2014","journal-title":"Proc Natl Acad Sci USA"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.02412","article-title":"A Viral-Vectored Multi-Stage Malaria Vaccine Regimen With Protective and Transmission-Blocking Efficacies","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front Immunol"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.00730","article-title":"Adeno-Associated Virus as an Effective Malaria Booster Vaccine Following Adenovirus Priming","volume":"10","author":"Yusuf","year":"2019","journal-title":"Front Immunol"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2014.172","article-title":"AAV8-Mediated In Vivo Overexpression of miR-155 Enhances the Protective Capacity of Genetically Attenuated Malarial Parasites","volume":"22","author":"Hentzschel","year":"2014","journal-title":"Mol Ther"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00202-19","article-title":"Single-Dose Vaccination With a Hepatotropic Adeno-Associated Virus Efficiently Localizes T Cell Immunity in the Liver With the Potential to Confer Rapid Protection Against Hepatitis C Virus","volume":"93","author":"Mekonnen","year":"2019","journal-title":"J Virol"},{"key":"B112","doi-asserted-by":"publisher","first-page":"e0142349","DOI":"10.1371\/journal.pone.0142349","article-title":"A Novel Adeno-Associated Virus-Based Genetic Vaccine Encoding the Hepatitis C Virus NS3\/4 Protein Exhibits Immunogenic Properties in Mice Superior to Those of an NS3-Protein-Based Vaccine","volume":"10","author":"Zhu","year":"2015","journal-title":"PloS One"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2018.9739","article-title":"Novel Adenoassociated Virusbased Genetic Vaccines Encoding Hepatitis C Virus E2 Glycoprotein Elicit Humoral Immune Responses in Mice","volume":"19","author":"Zhu","year":"2019","journal-title":"Mol Med Rep"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.139","article-title":"Long-Term Protection Against Human Papillomavirus e7-positive Tumor by a Single Vaccination of Adeno-Associated Virus Vectors Encoding a Fusion Protein of Inactivated E7 of Human Papillomavirus 16\/18 and Heat Shock Protein 70","volume":"21","author":"Zhou","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2011.202","article-title":"Intranasal Vaccination With AAV5 and 9 Vectors Against Human Papillomavirus Type 16 in Rhesus Macaques","volume":"23","author":"Nieto","year":"2012","journal-title":"Hum Gene Ther"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiw460","article-title":"Adeno-Associated Virus Serotype 9-Expressed ZMapp in Mice Confers Protection Against Systemic and Airway-Acquired Ebola Virus Infection","volume":"214","author":"Limberis","year":"2016","journal-title":"J Infect Dis"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.101","article-title":"Gene Transfer of ZMapp Antibodies Mediated by Recombinant Adeno-Associated Virus Protects Against Ebola Infections","volume":"29","author":"Robert","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jix644","article-title":"Intramuscular Adeno-Associated Virus-Mediated Expression of Monoclonal Antibodies Provides 100% Protection Against Ebola Virus Infection in Mice","volume":"217","author":"van Lieshout","year":"2018","journal-title":"J Infect Dis"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2017.06.020","article-title":"Dengue Virus Evades AAV-Mediated Neutralizing Antibody Prophylaxis in Rhesus Monkeys","volume":"25","author":"Magnani","year":"2017","journal-title":"Mol Ther"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2012.05.002","article-title":"Novel AAV-based Genetic Vaccines Encoding Truncated Dengue Virus Envelope Proteins Elicit Humoral Immune Responses in Mice","volume":"14","author":"Li","year":"2012","journal-title":"Microbes Infect"},{"key":"B121","doi-asserted-by":"publisher","DOI":"10.1099\/jgv.0.001351","article-title":"Use of Adeno-associated Viral Vectors to Improve Delivery of a DNA Vaccine Against Dengue Virus","volume":"101","author":"Slon-Campos","year":"2020","journal-title":"J Gen Virol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1099\/vir.0.83670-0","article-title":"Delivery of Single-Chain Antibodies (scFvs) Directed Against the 37\/67 kDa Laminin Receptor Into Mice Via Recombinant Adeno-Associated Viral Vectors for Prion Disease Gene Therapy","volume":"89","author":"Zuber","year":"2008","journal-title":"J Gen Virol"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.4161\/pri.20197","article-title":"Brain Delivery of AAV9 Expressing an anti-PrP Monovalent Antibody Delays Prion Disease in Mice","volume":"6","author":"Moda","year":"2012","journal-title":"Prion"},{"key":"B124","doi-asserted-by":"publisher","first-page":"108578","DOI":"10.1016\/j.vetmic.2020.108578","article-title":"AAV-Expressed G Protein Induces Robust Humoral and Cellular Immune Response and Provides Durable Protection From Rabies Virus Challenges in Mice","volume":"242","author":"Liu","year":"2020","journal-title":"Vet Microbiol"},{"key":"B125","doi-asserted-by":"publisher","DOI":"10.1021\/ac5022216","article-title":"Workflow for Combined Proteomics and Glycomics Profiling From Histological Tissues","volume":"86","author":"Turiak","year":"2014","journal-title":"Anal Chem"},{"key":"B126","doi-asserted-by":"publisher","first-page":"12144","DOI":"10.1038\/s41598-018-30358-0","article-title":"Engineering of Primary Human B Cells With CRISPR\/Cas9 Targeted Nuclease","volume":"8","author":"Johnson","year":"2018","journal-title":"Sci Rep"},{"key":"B127","doi-asserted-by":"publisher","first-page":"35495","DOI":"10.1038\/srep35495","article-title":"High-Efficiency Transduction of Primary Human Hematopoietic Stem\/Progenitor Cells by AAV6 Vectors: Strategies for Overcoming Donor-Variation and Implications in Genome Editing","volume":"6","author":"Ling","year":"2016","journal-title":"Sci Rep"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1038\/nrd3229","article-title":"Development Trends for Human Monoclonal Antibody Therapeutics","volume":"9","author":"Nelson","year":"2010","journal-title":"Nat Rev Drug Discovery"},{"key":"B129","unstructured":"Pfizer Presents Initial Clinical Data On Phase 1b Gene Therapy Study for Duchenne Muscular Dystrophy (Dmd)2019"},{"key":"B130","unstructured":"Solid Biosciences Provides SGT-001 Program2019"},{"key":"B131","doi-asserted-by":"publisher","first-page":"103728","DOI":"10.1016\/j.cellimm.2017.12.002","article-title":"Liver Induced Transgene Tolerance With AAV Vectors","volume":"342","author":"Keeler","year":"2019","journal-title":"Cell Immunol"},{"key":"B132","doi-asserted-by":"publisher","DOI":"10.1038\/cmi.2015.112","article-title":"Modulation of Liver Tolerance by Conventional and Nonconventional Antigen-Presenting Cells and Regulatory Immune Cells","volume":"13","author":"Horst","year":"2016","journal-title":"Cell Mol Immunol"},{"key":"B133","doi-asserted-by":"publisher","DOI":"10.1038\/sj.mt.6300142","article-title":"An Antibody Delivery System for Regulated Expression of Therapeutic Levels of Monoclonal Antibodies In Vivo","volume":"15","author":"Fang","year":"2007","journal-title":"Mol Ther"},{"key":"B134","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2004-06-2501","article-title":"Long-Term Pharmacologically Regulated Expression of Erythropoietin in Primates Following AAV-mediated Gene Transfer","volume":"105","author":"Rivera","year":"2005","journal-title":"Blood"},{"key":"B135","doi-asserted-by":"publisher","DOI":"10.1038\/mt.sj.6300079","article-title":"Rapamycin-Regulated Control of Antiangiogenic Tumor Therapy Following rAAV-mediated Gene Transfer","volume":"15","author":"Nguyen","year":"2007","journal-title":"Mol Ther"},{"key":"B136","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtm.2018.11.009","article-title":"A Self-Deleting Aav-Crispr System for In Vivo Genome Editing","volume":"12","author":"Li","year":"2019","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B137","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2017.95","article-title":"Strategy to Detect Pre-Existing Immunity to AAV Gene Therapy","volume":"24","author":"Falese","year":"2017","journal-title":"Gene Ther"},{"key":"B138","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.05107-11","article-title":"Adeno-Associated Virus Antibody Profiles in Newborns, Children, and Adolescents","volume":"18","author":"Calcedo","year":"2011","journal-title":"Clin Vaccine Immunol"},{"key":"B139","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of Serum IgG and Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 5, 6, 8, and 9 in the Healthy Population: Implications for Gene Therapy Using AAV Vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum Gene Ther"},{"key":"B140","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-017913","article-title":"Effects of Transient Immunosuppression on Adenoassociated, Virus-Mediated, Liver-Directed Gene Transfer in Rhesus Macaques and Implications for Human Gene Therapy","volume":"108","author":"Jiang","year":"2006","journal-title":"Blood"},{"key":"B141","doi-asserted-by":"publisher","DOI":"10.1038\/nm1358","article-title":"Successful Transduction of Liver in Hemophilia by AAV-Factor IX and Limitations Imposed by the Host Immune Response","volume":"12","author":"Manno","year":"2006","journal-title":"Nat Med"},{"key":"B142","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-08-3229","article-title":"Human Immunoglobulin Inhibits Liver Transduction by AAV Vectors At Low AAV2 Neutralizing Titers in SCID Mice","volume":"107","author":"Scallan","year":"2006","journal-title":"Blood"},{"key":"B143","doi-asserted-by":"publisher","DOI":"10.1038\/nm1549","article-title":"Cd8(+) T-cell Responses to Adeno-Associated Virus Capsid in Humans","volume":"13","author":"Mingozzi","year":"2007","journal-title":"Nat Med"},{"key":"B144","doi-asserted-by":"publisher","DOI":"10.2174\/156652311796150354","article-title":"Immune Responses to AAV in Clinical Trials","volume":"11","author":"Mingozzi","year":"2011","journal-title":"Curr Gene Ther"},{"key":"B145","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-167510","article-title":"Aav-1-mediated Gene Transfer to Skeletal Muscle in Humans Results in Dose-Dependent Activation of Capsid-Specific T Cells","volume":"114","author":"Mingozzi","year":"2009","journal-title":"Blood"},{"key":"B146","doi-asserted-by":"publisher","DOI":"10.1172\/JCI70314","article-title":"Human Treg Responses Allow Sustained Recombinant Adeno-Associated Virus-Mediated Transgene Expression","volume":"123","author":"Mueller","year":"2013","journal-title":"J Clin Invest"},{"key":"B147","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV Gene Transfer From Neutralizing Antibodies With an IgG-degrading Enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"B148","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving Endopeptidase Enables In Vivo Gene Therapy in the Presence of anti-AAV Neutralizing Antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat Med"},{"key":"B149","doi-asserted-by":"publisher","first-page":"4098","DOI":"10.1038\/s41467-018-06621-3","article-title":"Antigen-Selective Modulation of AAV Immunogenicity With Tolerogenic Rapamycin Nanoparticles Enables Successful Vector Re-Administration","volume":"9","author":"Meliani","year":"2018","journal-title":"Nat Commun"},{"key":"B150","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.copbio.2019.01.002","article-title":"Engineering the AAV Capsid to Evade Immune Responses","volume":"60","author":"Barnes","year":"2019","journal-title":"Curr Opin Biotechnol"},{"key":"B151","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1089\/hgtb.2012.243","article-title":"Pre-Existing Anti-Adeno-Associated Virus Antibodies as a Challenge in AAV Gene Therapy","volume":"24","author":"Louis Jeune","year":"2013","journal-title":"Hum Gene Ther Methods"},{"key":"B152","doi-asserted-by":"publisher","first-page":"189ra76","DOI":"10.1126\/scitranslmed.3005708","article-title":"In Vivo-Directed Evolution of a New Adeno-Associated Virus for Therapeutic Outer Retinal Gene Delivery From the Vitreous","volume":"5","author":"Dalkara","year":"2013","journal-title":"Sci Transl Med"},{"key":"B153","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1704766114","article-title":"Structure-Guided Evolution of Antigenically Distinct Adeno-Associated Virus Variants for Immune Evasion","volume":"114","author":"Tse","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"B154","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.19.9281-9293.2000","article-title":"Monoclonal Antibodies Against the Adeno-Associated Virus Type 2 (AAV-2) Capsid: Epitope Mapping and Identification of Capsid Domains Involved in AAV-2-cell Interaction and Neutralization of AAV-2 Infection","volume":"74","author":"Wobus","year":"2000","journal-title":"J Virol"},{"key":"B155","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00675-12","article-title":"Single Amino Acid Modification of Adeno-Associated Virus Capsid Changes Transduction and Humoral Immune Profiles","volume":"86","author":"Li","year":"2012","journal-title":"J Virol"},{"key":"B156","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1038\/nbt1182","article-title":"Directed Evolution of Adeno-Associated Virus Yields Enhanced Gene Delivery Vectors","volume":"24","author":"Maheshri","year":"2006","journal-title":"Nat Biotechnol"},{"key":"B157","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00254-08","article-title":"In Vitro and In Vivo Gene Therapy Vector Evolution Via Multispecies Interbreeding and Retargeting of Adeno-Associated Viruses","volume":"82","author":"Grimm","year":"2008","journal-title":"J Virol"},{"key":"B158","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ymthe.2017.09.021","article-title":"Bioengineered AAV Capsids With Combined High Human Liver Transduction in Vivo and Unique Humoral Seroreactivity","volume":"26","author":"Paulk","year":"2018","journal-title":"Mol Ther"},{"key":"B159","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.108","article-title":"A 10 Patient Case Report on the Impact of Plasmapheresis Upon Neutralizing Factors Against Adeno-Associated Virus (AAV) Types 1, 2, 6, and 8","volume":"19","author":"Monteilhet","year":"2011","journal-title":"Mol Ther"},{"key":"B160","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2013.244","article-title":"Plasmapheresis Eliminates the Negative Impact of AAV Antibodies on Microdystrophin Gene Expression Following Vascular Delivery","volume":"22","author":"Chicoine","year":"2014","journal-title":"Mol Ther"},{"key":"B161","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41598-020-57893-z","article-title":"Capsid-Specific Removal of Circulating Antibodies to Adeno-Associated Virus Vectors","volume":"10","author":"Bertin","year":"2020","journal-title":"Sci Rep"},{"key":"B162","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the Complex Story of Immune Responses to AAV Vectors Trial After Trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum Gene Ther"},{"key":"B163","doi-asserted-by":"publisher","first-page":"194ra92","DOI":"10.1126\/scitranslmed.3005795","article-title":"Overcoming Preexisting Humoral Immunity to AAV Using Capsid Decoys","volume":"5","author":"Mingozzi","year":"2013","journal-title":"Sci Transl Med"},{"key":"B164","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-06-437202","article-title":"Peptide Length Determines the Outcome of TCR\/peptide-MHCI Engagement","volume":"121","author":"Ekeruche-Makinde","year":"2013","journal-title":"Blood"},{"key":"B165","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2020.29117.trf","article-title":"Revisiting the \u201cNew\u201d Inflammatory Toxicities of Adeno-Associated Virus Vectors","volume":"31","author":"Flotte","year":"2020","journal-title":"Hum Gene Ther"},{"key":"B166","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.omtm.2018.06.003","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Human Alpha-L-Iduronidase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B167","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.omtm.2018.06.004","article-title":"Toxicology Study of Intra-Cisterna Magna Adeno-Associated Virus 9 Expressing Iduronate-2-Sulfatase in Rhesus Macaques","volume":"10","author":"Hordeaux","year":"2018","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B168","doi-asserted-by":"publisher","DOI":"10.1089\/hum.2018.015","article-title":"Severe Toxicity in Nonhuman Primates and Piglets Following High-Dose Intravenous Administration of an Adeno-Associated Virus Vector Expressing Human Smn","volume":"29","author":"Hinderer","year":"2018","journal-title":"Hum Gene Ther"},{"key":"B169","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci10020119","article-title":"Management of Neuroinflammatory Responses to AAV-Mediated Gene Therapies for Neurodegenerative Diseases","volume":"10","author":"Perez","year":"2020","journal-title":"Brain Sci"},{"key":"B170","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1706198","article-title":"Single-Dose Gene-Replacement Therapy for Spinal Muscular Atrophy","volume":"377","author":"Mendell","year":"2017","journal-title":"N Engl J Med"},{"key":"B171","unstructured":"Audentes Announces Positive Interim Data From First Dose Cohort of ASPIRO, a Phase 1\/2 Clinical Trial of AT132 in Patients With X-Linked Myotubular Myopathy"},{"key":"B172","volume-title":"Solid Bio Sees Yet Another Clinical Hold for its DMD Gene Therapy","author":"Hale","year":"2019"},{"key":"B173","unstructured":"Pfizer\u2019s New Phase 1b Results of Gene Therapy In Ambulatory Boys With Duchenne Muscular Dystrophy (Dmd) Support Advancement Into Pivotal Phase 3 Study"},{"key":"B174","doi-asserted-by":"publisher","DOI":"10.3390\/v11020102","article-title":"Adeno-Associated Virus (AAV) Versus Immune Response","volume":"11","author":"Rabinowitz","year":"2019","journal-title":"Viruses"},{"key":"B175","doi-asserted-by":"publisher","DOI":"10.1172\/JCI37607","article-title":"The TLR9-MyD88 Pathway is Critical for Adaptive Immune Responses to Adeno-Associated Virus Gene Therapy Vectors in Mice","volume":"119","author":"Zhu","year":"2009","journal-title":"J Clin Invest"},{"key":"B176","doi-asserted-by":"publisher","first-page":"2994","DOI":"10.1172\/JCI68205","article-title":"CpG-depleted Adeno-Associated Virus Vectors Evade Immune Detection","volume":"123","author":"Faust","year":"2013","journal-title":"J Clin Invest"},{"key":"B177","doi-asserted-by":"publisher","first-page":"103997","DOI":"10.1016\/j.cellimm.2019.103997","article-title":"TLR9 Signaling Mediates Adaptive Immunity Following Systemic AAV Gene Therapy","volume":"346","author":"Ashley","year":"2019","journal-title":"Cell Immunol"},{"key":"B178","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-11-751040","article-title":"Plasmacytoid and Conventional Dendritic Cells Cooperate in Crosspriming AAV Capsid-Specific CD8(+) T Cells","volume":"129","author":"Rogers","year":"2017","journal-title":"Blood"},{"key":"B179","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1089\/hgtb.2019.013","article-title":"Tlr9-Activating CpG-B ODN But Not Tlr7 Agonists Triggers Antibody Formation to Factor IX in Muscle Gene Transfer","volume":"30","author":"Butterfield","year":"2019","journal-title":"Hum Gene Ther Methods"},{"key":"B180","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2010-10-314518","article-title":"The Genome of Self-Complementary Adeno-Associated Viral Vectors Increases Toll-like Receptor 9-Dependent Innate Immune Responses in the Liver","volume":"117","author":"Martino","year":"2011","journal-title":"Blood"},{"key":"B181","doi-asserted-by":"publisher","DOI":"10.1002\/hep.24625","article-title":"Toll-Like Receptor 2-Mediated Innate Immune Response in Human Nonparenchymal Liver Cells Toward Adeno-Associated Viral Vectors","volume":"55","author":"Hosel","year":"2012","journal-title":"Hepatology"},{"key":"B182","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2012.101","article-title":"MyD88 Signaling in B Cells Regulates the Production of Th1-dependent Antibodies to AAV","volume":"20","author":"Sudres","year":"2012","journal-title":"Mol Ther"},{"key":"B183","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abd3438","article-title":"Engineering Adeno-Associated Viral Vectors to Evade Innate Immune and Inflammatory Responses","volume":"13","author":"Chan","year":"2021","journal-title":"Sci Transl Med"},{"key":"B184","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.99052","article-title":"Circumventing Cellular Immunity by miR142-mediated Regulation Sufficiently Supports Raav-Delivered OVA Expression Without Activating Humoral Immunity","volume":"5","author":"Xiao","year":"2019","journal-title":"JCI Insight"},{"key":"B185","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1089\/hum.2012.208","article-title":"Prolonged Gene Expression in Muscle is Achieved Without Active Immune Tolerance Using microrRNA 142.3p-regulated rAAV Gene Transfer","volume":"24","author":"Boisgerault","year":"2013","journal-title":"Hum Gene Ther"},{"key":"B186","doi-asserted-by":"publisher","DOI":"10.1101\/2021.01.05.422952","article-title":"Immunogenicity of an AAV-based, Room-Temperature Stable, Single Dose COVID-19 Vaccine in Mice and non-Human Primates","author":"Zabaleta","year":"2021","journal-title":"bioRxiv"},{"key":"B187","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.280","article-title":"Self-Complementary AAVs Induce More Potent Transgene Product-Specific Immune Responses Compared to a Single-Stranded Genome","volume":"20","author":"Wu","year":"2012","journal-title":"Mol Ther"},{"key":"B188","doi-asserted-by":"publisher","DOI":"10.1089\/gen.40.09.04","article-title":"Genetic Engineering & Biotechnology News","volume":"40","author":"Paulk","year":"2020"},{"key":"B189","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.omtm.2020.05.018","article-title":"Methods Matter: Standard Production Platforms for Recombinant Aav Produce Chemically and Functionally Distinct Vectors","volume":"18","author":"Rumachik","year":"2020","journal-title":"Mol Ther Methods Clin Dev"},{"key":"B190","doi-asserted-by":"publisher","DOI":"10.1038\/gt.2009.157","article-title":"High AAV Vector Purity Results in Serotype- and Tissue-Independent Enhancement of Transduction Efficiency","volume":"17","author":"Ayuso","year":"2010","journal-title":"Gene Ther"},{"key":"B191","unstructured":"Hiv\/Aids 2020"},{"key":"B192","doi-asserted-by":"publisher","DOI":"10.1038\/nrmicro3490","article-title":"HIV-1 Assembly, Release and Maturation","volume":"13","author":"Freed","year":"2015","journal-title":"Nat Rev Microbiol"},{"key":"B193","doi-asserted-by":"publisher","DOI":"10.1016\/S0092-8674(00)80205-6","article-title":"Core Structure of gp41 From the HIV Envelope Glycoprotein","volume":"89","author":"Chan","year":"1997","journal-title":"Cell"},{"key":"B194","doi-asserted-by":"publisher","DOI":"10.1021\/cb600131q","article-title":"Following the Path of the Virus: The Exploitation of Host DNA Repair Mechanisms by Retroviruses","volume":"1","author":"Smith","year":"2006","journal-title":"ACS Chem Biol"},{"key":"B195","doi-asserted-by":"publisher","first-page":"597","DOI":"10.12688\/f1000research.10876.1","article-title":"Recent Advances in Understanding HIV Evolution","volume":"6","author":"Andrews","year":"2017","journal-title":"F1000Res"},{"key":"B196","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000475","article-title":"Broadly Neutralizing Antibodies for Treatment and Prevention of HIV-1 Infection","volume":"13","author":"Cohen","year":"2018","journal-title":"Curr Opin HIV AIDS"},{"key":"B197","doi-asserted-by":"publisher","first-page":"e1000908","DOI":"10.1371\/journal.ppat.1000908","article-title":"Few and Far Between: How HIV may be Evading Antibody Avidity","volume":"6","author":"Klein","year":"2010","journal-title":"PloS Pathog"},{"key":"B198","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-031210-101400","article-title":"Follicular Helper CD4 T Cells (TFH)","volume":"29","author":"Crotty","year":"2011","journal-title":"Annu Rev Immunol"},{"key":"B199","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132494","article-title":"Passive Transfer of Modest Titers of Potent and Broadly Neutralizing anti-HIV Monoclonal Antibodies Block SHIV Infection in Macaques","volume":"211","author":"Shingai","year":"2014","journal-title":"J Exp Med"},{"key":"B200","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0186-4","article-title":"Safety and Antiviral Activity of Combination HIV-1 Broadly Neutralizing Antibodies in Viremic Individuals","volume":"24","author":"Bar-On","year":"2018","journal-title":"Nat Med"},{"key":"B201","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2","article-title":"Combination Therapy With anti-HIV-1 Antibodies Maintains Viral Suppression","volume":"561","author":"Mendoza","year":"2018","journal-title":"Nature"},{"key":"B202","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0412-8","article-title":"Broadly Neutralizing anti-HIV-1 Monoclonal Antibodies in the Clinic","volume":"25","author":"Caskey","year":"2019","journal-title":"Nat Med"},{"key":"B203","unstructured":"Prevention CfDCa. Past Seasons Estimated Influenza Disease Burden"},{"key":"B204","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1177\/0885066602250368","article-title":"Influenza in the Intensive Care Unit","volume":"18","author":"Oliveira","year":"2003","journal-title":"J\u00a0Intensive Care Med"},{"key":"B205","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/S1473-3099(11)70295-X","article-title":"Efficacy and Effectiveness of Influenza Vaccines: A Systematic Review and Meta-Analysis","volume":"12","author":"Osterholm","year":"2012","journal-title":"Lancet Infect Dis"},{"key":"B206","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2013.09.063","article-title":"Cochrane Re-Arranged: Support for Policies to Vaccinate Elderly People Against Influenza","volume":"31","author":"Beyer","year":"2013","journal-title":"Vaccine"},{"key":"B207","doi-asserted-by":"publisher","DOI":"10.1038\/nature03974","article-title":"Avian Flu: H5N1 Virus Outbreak in Migratory Waterfowl","volume":"436","author":"Chen","year":"2005","journal-title":"Nature"},{"key":"B208","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-018-0002-y","article-title":"Influenza","volume":"4","author":"Krammer","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B209","doi-asserted-by":"publisher","first-page":"C8","DOI":"10.1016\/j.vaccine.2008.04.011","article-title":"Vaccination and Antigenic Drift in Influenza","volume":"26","author":"Boni","year":"2008","journal-title":"Vaccine"},{"key":"B210","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(82)90135-0","article-title":"The Antigenic Structure of the Influenza Virus A\/PR\/8\/34 Hemagglutinin (H1 Subtype)","volume":"31","author":"Caton","year":"1982","journal-title":"Cell"},{"key":"B211","doi-asserted-by":"publisher","DOI":"10.1126\/science.1205669","article-title":"A Neutralizing Antibody Selected From Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins","volume":"333","author":"Corti","year":"2011","journal-title":"Science"},{"key":"B212","doi-asserted-by":"publisher","DOI":"10.1126\/science.1222908","article-title":"Highly Conserved Protective Epitopes on Influenza B Viruses","volume":"337","author":"Dreyfus","year":"2012","journal-title":"Science"},{"key":"B213","doi-asserted-by":"publisher","DOI":"10.1126\/science.1204839","article-title":"A Highly Conserved Neutralizing Epitope on Group 2 Influenza A Viruses","volume":"333","author":"Ekiert","year":"2011","journal-title":"Science"},{"key":"B214","doi-asserted-by":"publisher","DOI":"10.1126\/science.1171491","article-title":"Antibody Recognition of a Highly Conserved Influenza Virus Epitope","volume":"324","author":"Ekiert","year":"2009","journal-title":"Science"},{"key":"B215","doi-asserted-by":"publisher","first-page":"e80034","DOI":"10.1371\/journal.pone.0080034","article-title":"Mechanisms of Hemagglutinin Targeted Influenza Virus Neutralization","volume":"8","author":"Brandenburg","year":"2013","journal-title":"PloS One"},{"key":"B216","doi-asserted-by":"publisher","DOI":"10.1038\/nature07231","article-title":"Neutralizing Antibodies Derived From the B Cells of 1918 Influenza Pandemic Survivors","volume":"455","author":"Yu","year":"2008","journal-title":"Nature"},{"key":"B217","doi-asserted-by":"publisher","DOI":"10.1038\/nsmb.1566","article-title":"Structural and Functional Bases for Broad-Spectrum Neutralization of Avian and Human Influenza A Viruses","volume":"16","author":"Sui","year":"2009","journal-title":"Nat Struct Mol Biol"},{"key":"B218","doi-asserted-by":"publisher","DOI":"10.1038\/nm.3443","article-title":"Broadly Neutralizing Hemagglutinin Stalk-Specific Antibodies Require FcgammaR Interactions for Protection Against Influenza Virus In Vivo","volume":"20","author":"DiLillo","year":"2014","journal-title":"Nat Med"},{"key":"B219","doi-asserted-by":"publisher","first-page":"e3942","DOI":"10.1371\/journal.pone.0003942","article-title":"Heterosubtypic Neutralizing Monoclonal Antibodies Cross-Protective Against H5N1 and H1N1 Recovered From Human IgM+ Memory B Cells","volume":"3","author":"Throsby","year":"2008","journal-title":"PloS One"},{"key":"B220","doi-asserted-by":"publisher","DOI":"10.1038\/mt.2011.146","article-title":"Intranasal Administration of Adeno-Associated Virus Type 12 (AAV12) Leads to Transduction of the Nasal Epithelia and can Initiate Transgene-Specific Immune Response","volume":"19","author":"Quinn","year":"2011","journal-title":"Mol Ther"},{"key":"B221","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.mi.44.100190.003245","article-title":"Flavivirus Genome Organization, Expression, and Replication","volume":"44","author":"Chambers","year":"1990","journal-title":"Annu Rev Microbiol"},{"key":"B222","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2147\/CLEP.S34440","article-title":"Epidemiology of Dengue: Past, Present and Future Prospects","volume":"5","author":"Murray","year":"2013","journal-title":"Clin Epidemiol"},{"key":"B223","doi-asserted-by":"publisher","DOI":"10.1038\/nature12060","article-title":"The Global Distribution and Burden of Dengue","volume":"496","author":"Bhatt","year":"2013","journal-title":"Nature"},{"key":"B224","unstructured":"Dengue and Severe Dengue2020"},{"key":"B225","doi-asserted-by":"publisher","DOI":"10.1126\/science.aai8128","article-title":"Igg Antibodies to Dengue Enhanced for FcgammaRIIIA Binding Determine Disease Severity","volume":"355","author":"Wang","year":"2017","journal-title":"Science"},{"key":"B226","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2020.572681","article-title":"Antibody-Dependent Enhancement: A Challenge for Developing a Safe Dengue Vaccine","volume":"10","author":"Shukla","year":"2020","journal-title":"Front Cell Infect Microbiol"},{"key":"B227","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens9040247","article-title":"Non-Human Primate Models of Dengue Virus Infection: A Comparison of Viremia Levels and Antibody Responses During Primary and Secondary Infection Among Old World and New World Monkeys","volume":"9","author":"Muhammad Azami","year":"2020","journal-title":"Pathogens"},{"key":"B228","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00216-15","article-title":"Dengue Virus Infection With Highly Neutralizing Levels of Cross-Reactive Antibodies Causes Acute Lethal Small Intestinal Pathology Without a High Level of Viremia in Mice","volume":"89","author":"Watanabe","year":"2015","journal-title":"J Virol"},{"key":"B229","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6836","article-title":"Antibody-Dependent Enhancement of Severe Dengue Disease in Humans","volume":"358","author":"Katzelnick","year":"2017","journal-title":"Science"},{"key":"B230","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0157-4","article-title":"Reconstruction of Antibody Dynamics and Infection Histories to Evaluate Dengue Risk","volume":"557","author":"Salje","year":"2018","journal-title":"Nature"},{"key":"B231","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1800820","article-title":"Effect of Dengue Serostatus on Dengue Vaccine Safety and Efficacy","volume":"379","author":"Sridhar","year":"2018","journal-title":"N Engl J Med"},{"key":"B232","doi-asserted-by":"publisher","DOI":"10.3389\/fcimb.2019.00200","article-title":"Molecular Simulations Reveal the Role of Antibody Fine Specificity and Viral Maturation State on Antibody-Dependent Enhancement of Infection in Dengue Virus","volume":"9","author":"Ripoll","year":"2019","journal-title":"Front Cell Infect Microbiol"},{"key":"B233","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1038\/s41541-016-0003-3","article-title":"A Potent Neutralizing Antibody With Therapeutic Potential Against All Four Serotypes of Dengue Virus","volume":"2","author":"Xu","year":"2017","journal-title":"NPJ Vaccines"},{"key":"B234","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2010.08.007","article-title":"The Human Immune Response to Dengue Virus is Dominated by Highly Cross-Reactive Antibodies Endowed With Neutralizing and Enhancing Activity","volume":"8","author":"Beltramello","year":"2010","journal-title":"Cell Host Microbe"},{"key":"B235","doi-asserted-by":"publisher","first-page":"e1003157","DOI":"10.1371\/journal.ppat.1003157","article-title":"Therapeutic Efficacy of Antibodies Lacking Fcgamma Receptor Binding Against Lethal Dengue Virus Infection is Due to Neutralizing Potency and Blocking of Enhancing Antibodies [Corrected]","volume":"9","author":"Williams","year":"2013","journal-title":"PloS Pathog"},{"key":"B236","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical Course and Outcomes of Critically Ill Patients With SARS-CoV-2 Pneumonia in Wuhan, China: A Single-Centered, Retrospective, Observational Study","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir Med"},{"key":"B237","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2798-3","article-title":"Sars-CoV-2 Vaccines in Development","volume":"586","author":"Krammer","year":"2020","journal-title":"Nature"},{"key":"B238","unstructured":"Coronavirus Disease (COVID-2019) Situation Reports"},{"key":"B239","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2001017","article-title":"A Novel Coronavirus From Patients With Pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"B240","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM Structure of the 2019-Ncov Spike in the Prefusion Conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"B241","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.123158","article-title":"Anti-Spike IgG Causes Severe Acute Lung Injury by Skewing Macrophage Responses During Acute SARS-CoV Infection","volume":"4","author":"Liu","year":"2019","journal-title":"JCI Insight"},{"key":"B242","doi-asserted-by":"publisher","DOI":"10.1021\/acsinfecdis.6b00006","article-title":"Immunodominant SARS Coronavirus Epitopes in Humans Elicited Both Enhancing and Neutralizing Effects on Infection in Non-human Primates","volume":"2","author":"Wang","year":"2016","journal-title":"ACS Infect Dis"},{"key":"B243","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2005.06.038","article-title":"Immunogenicity and Protective Efficacy in Monkeys of Purified Inactivated Vero-cell SARS Vaccine","volume":"24","author":"Qin","year":"2006","journal-title":"Vaccine"},{"key":"B244","doi-asserted-by":"publisher","DOI":"10.1007\/s12250-018-0009-2","article-title":"Evaluation of Antibody-Dependent Enhancement of SARS-CoV Infection in Rhesus Macaques Immunized With an Inactivated Sars-CoV Vaccine","volume":"33","author":"Luo","year":"2018","journal-title":"Virol Sin"},{"key":"B245","doi-asserted-by":"publisher","first-page":"01.07.425740","DOI":"10.1101\/2021.01.07.425740","article-title":"Neutralization of N501Y Mutant SARS-CoV-2 by BNT162b2 Vaccine-Elicited Sera","volume":"2021","author":"Xie","year":"2021","journal-title":"bioRxiv"},{"key":"B246","doi-asserted-by":"publisher","first-page":"12.09.20245175","DOI":"10.1101\/2020.12.09.20245175","article-title":"BNT162b2 Induces SARS-CoV-2-neutralising Antibodies and T Cells in Humans","volume":"2020","author":"Sahin","year":"2020","journal-title":"medRxiv"},{"key":"B247","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2032195","article-title":"Durability of Responses After SARS-CoV-2 mRNA-1273 Vaccination","volume":"384","author":"Widge","year":"2021","journal-title":"N Engl J Med"},{"key":"B248","unstructured":"Massachusetts Eye and Ear and Massachusetts General Hospital Advancing Novel Experimental Gene-based Covid-19 Vaccine, Aavcovid"},{"key":"B249","doi-asserted-by":"publisher","DOI":"10.1086\/595830","article-title":"Worldwide Epidemiology of Neutralizing Antibodies to Adeno-Associated Viruses","volume":"199","author":"Calcedo","year":"2009","journal-title":"J Infect Dis"},{"key":"B250","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00596-13","article-title":"Mapping the Structural Determinants Responsible for Enhanced T Cell Activation to the Immunogenic Adeno-Associated Virus Capsid From Isolate Rhesus 32","volume":"87","author":"Mays","year":"2013","journal-title":"33 J Virol"},{"key":"B251","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01441-09","article-title":"A New Genetic Vaccine Platform Based on an Adeno-Associated Virus Isolated From a Rhesus Macaque","volume":"83","author":"Lin","year":"2009","journal-title":"J Virol"},{"key":"B252","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Studies in Humanized Mice and Convalescent Humans Yield a SARS-CoV-2 Antibody Cocktail","volume":"369","author":"Hansen","year":"2020","journal-title":"Science"},{"key":"B253","doi-asserted-by":"publisher","DOI":"10.1126\/science.abd0831","article-title":"Antibody Cocktail to SARS-CoV-2 Spike Protein Prevents Rapid Mutational Escape Seen With Individual Antibodies","volume":"369","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B254","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035002","article-title":"Regn-COV2, a Neutralizing Antibody Cocktail, in Outpatients With Covid-19","volume":"384","author":"Weinreich","year":"2021","journal-title":"N Engl J Med"},{"key":"B255","unstructured":"Coronavirus (COVID-19) Update: Fda Authorizes Monoclonal Antibodies for Treatment of COVID-192020"},{"key":"B256","unstructured":"Penn Medicine Collaborates With Regeneron to Investigate Delivery of COVID-19 Antibody Cocktail Via Gene Therapy Platform2020"},{"key":"B257","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1146\/annurev.pathmechdis.3.121806.154326","article-title":"Molecular Mechanisms of Prion Pathogenesis","volume":"3","author":"Aguzzi","year":"2008","journal-title":"Annu Rev Pathol"},{"key":"B258","doi-asserted-by":"publisher","DOI":"10.1038\/nature01457","article-title":"Monoclonal Antibodies Inhibit Prion Replication and Delay the Development of Prion Disease","volume":"422","author":"White","year":"2003","journal-title":"Nature"},{"key":"B259","doi-asserted-by":"publisher","DOI":"10.1016\/S0304-3940(02)01192-8","article-title":"Anti-Prion Antibodies for Prophylaxis Following Prion Exposure in Mice","volume":"336","author":"Sigurdsson","year":"2003","journal-title":"Neurosci Lett"},{"key":"B260","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0803671105","article-title":"A Gamma-Secretase Inhibitor and Quinacrine Reduce Prions and Prevent Dendritic Degeneration in Murine Brains","volume":"105","author":"Spilman","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"B261","doi-asserted-by":"publisher","first-page":"e39112","DOI":"10.1371\/journal.pone.0039112","article-title":"Pharmacokinetics of Quinacrine Efflux From Mouse Brain Via the P-glycoprotein Efflux Transporter","volume":"7","author":"Ahn","year":"2012","journal-title":"PloS One"},{"key":"B262","doi-asserted-by":"publisher","DOI":"10.1126\/science.1094273","article-title":"Cross-Linking Cellular Prion Protein Triggers Neuronal Apoptosis In Vivo","volume":"303","author":"Solforosi","year":"2004","journal-title":"Science"},{"key":"B263","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1126\/science.1215579","article-title":"Prp Antibodies do Not Trigger Mouse Hippocampal Neuron Apoptosis","volume":"335","author":"Klohn","year":"2012","journal-title":"Science"},{"key":"B264","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0404772101","article-title":"Humoral Immune Response to Native Eukaryotic Prion Protein Correlates With Anti-Prion Protection","volume":"101","author":"Polymenidou","year":"2004","journal-title":"Proc Natl Acad Sci USA"},{"key":"B265","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.neuron.2019.03.020","article-title":"Therapeutic AAV Gene Transfer to the Nervous System: A Clinical Reality","volume":"102","author":"Hudry","year":"2019","journal-title":"Neuron"},{"key":"B266","doi-asserted-by":"publisher","DOI":"10.1042\/BJ20081541","article-title":"Development of Antibody Fragments for Immunotherapy of Prion Diseases","volume":"418","author":"Campana","year":"2009","journal-title":"Biochem J"},{"key":"B267","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1016\/bs.aivir.2017.12.002","article-title":"Filoviruses: Ecology, Molecular Biology, and Evolution","volume":"100","author":"Emanuel","year":"2018","journal-title":"Adv Virus Res"},{"key":"B268","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and Effectiveness of an rVSV-vectored Vaccine in Preventing Ebola Virus Disease: Final Results From the Guinea Ring Vaccination, Open-Label, Cluster-Randomised Trial (Ebola Ca Suffit","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"B269","doi-asserted-by":"publisher","DOI":"10.3390\/tropicalmed5040169","article-title":"Aav Vectored Immunoprophylaxis for Filovirus Infections","volume":"5","author":"Rghei","year":"2020","journal-title":"Trop Med Infect Dis"},{"key":"B270","doi-asserted-by":"publisher","first-page":"e1575","DOI":"10.1371\/journal.pntd.0001575","article-title":"Ebola GP-specific Monoclonal Antibodies Protect Mice and Guinea Pigs From Lethal Ebola Virus Infection","volume":"6","author":"Qiu","year":"2012","journal-title":"PloS Negl Trop Dis"},{"key":"B271","doi-asserted-by":"publisher","first-page":"138ra81","DOI":"10.1126\/scitranslmed.3003876","article-title":"Successful Treatment of Ebola Virus-Infected Cynomolgus Macaques With Monoclonal Antibodies","volume":"4","author":"Qiu","year":"2012","journal-title":"Sci Transl Med"},{"key":"B272","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02171-15","article-title":"Pan-Ebolavirus and Pan-filovirus Mouse Monoclonal Antibodies: Protection Against Ebola and Sudan Viruses","volume":"90","author":"Holtsberg","year":"2016","journal-title":"J Virol"},{"key":"B273","doi-asserted-by":"publisher","DOI":"10.1126\/science.aad5224","article-title":"Protective Monotherapy Against Lethal Ebola Virus Infection by a Potently Neutralizing Antibody","volume":"351","author":"Corti","year":"2016","journal-title":"Science"},{"key":"B274","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.77.18.9733-9737.2003","article-title":"Ebola Virus Pathogenesis: Implications for Vaccines and Therapies","volume":"77","author":"Sullivan","year":"2003","journal-title":"J Virol"},{"key":"B275","doi-asserted-by":"publisher","DOI":"10.3201\/eid0810.020329","article-title":"Investigation of Bioterrorism-Related Anthrax, United States, 2001: Epidemiologic Findings","volume":"8","author":"Jernigan","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"B276","doi-asserted-by":"publisher","DOI":"10.1136\/thoraxjnl-2018-212212","article-title":"Respiratory Syncytial Virus (RSV): A Scourge From Infancy to Old Age","volume":"74","author":"Coultas","year":"2019","journal-title":"Thorax"},{"key":"B277","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.mib.2003.12.001","article-title":"The Roles of Anthrax Toxin in Pathogenesis","volume":"7","author":"Moayeri","year":"2004","journal-title":"Curr Opin Microbiol"},{"key":"B278","doi-asserted-by":"publisher","DOI":"10.1172\/JCI44423","article-title":"Advances and Challenges in Malaria Vaccine Development","volume":"120","author":"Crompton","year":"2010","journal-title":"J Clin Invest"},{"key":"B279","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)62238-2","article-title":"Malaria Vaccine Technology Roadmap","volume":"382","author":"Moorthy","year":"2013","journal-title":"Lancet"},{"key":"B280","doi-asserted-by":"publisher","first-page":"e61395","DOI":"10.1371\/journal.pone.0061395","article-title":"The Relationship Between RTS,S Vaccine-Induced Antibodies, CD4(+) T Cell Responses and Protection Against Plasmodium Falciparum Infection","volume":"8","author":"White","year":"2013","journal-title":"PloS One"},{"key":"B281","doi-asserted-by":"publisher","DOI":"10.1126\/science.1184785","article-title":"That was Then But This is Now: Malaria Research in the Time of an Eradication Agenda","volume":"328","author":"Kappe","year":"2010","journal-title":"Science"},{"key":"B282","doi-asserted-by":"publisher","DOI":"10.1042\/ETLS20170117","article-title":"A Whole Parasite Transmission-Blocking Vaccine for Malaria: An Ignored Strategy","volume":"1","author":"Good","year":"2017","journal-title":"Emerg Top Life Sci"},{"key":"B283","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.02780","article-title":"Combination of RTS,S and Pfs25-IMX313 Induces a Functional Antibody Response Against Malaria Infection and Transmission in Mice","volume":"9","author":"Brod","year":"2018","journal-title":"Front Immunol"},{"key":"B284","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v7.i6.831","article-title":"Hepatitis C Virus Genetic Variability and Evolution","volume":"7","author":"Echeverria","year":"2015","journal-title":"World J Hepatol"},{"key":"B285","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.07089-11","article-title":"Hepatitis C Virus Nonstructural Protein 5B is Involved in Virus Morphogenesis","volume":"86","author":"Gouklani","year":"2012","journal-title":"J Virol"},{"key":"B286","doi-asserted-by":"publisher","first-page":"17091","DOI":"10.1038\/nrdp.2017.91","article-title":"Rabies","volume":"3","author":"Fooks","year":"2017","journal-title":"Nat Rev Dis Primers"},{"key":"B287","doi-asserted-by":"publisher","DOI":"10.1586\/14760584.2016.1140040","article-title":"Current Status and Development of Vaccines and Other Biologics for Human Rabies Prevention","volume":"15","author":"Rupprecht","year":"2016","journal-title":"Expert Rev Vaccines"},{"key":"B288","doi-asserted-by":"publisher","first-page":"e0003709","DOI":"10.1371\/journal.pntd.0003709","article-title":"Estimating the Global Burden of Endemic Canine Rabies","volume":"9","author":"Hampson","year":"2015","journal-title":"PloS Negl Trop Dis"},{"key":"B289","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines8040597","article-title":"From the Infection to the Immunotherapy in Cervical Cancer: Can We Stop the Natural Course of the Disease","volume":"8","author":"Luvero","year":"2020","journal-title":"Vaccines (Basel)"},{"key":"B290","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(13)60022-7","article-title":"Human Papillomavirus and Cervical Cancer","volume":"382","author":"Crosbie","year":"2013","journal-title":"Lancet"},{"key":"B291","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s11262-009-0412-8","article-title":"The Biological Properties of E6 and E7 Oncoproteins From Human Papillomaviruses","volume":"40","author":"Ghittoni","year":"2010","journal-title":"Virus Genes"},{"key":"B292","doi-asserted-by":"publisher","DOI":"10.1002\/humu.10178","article-title":"The Role of TP53 in Cervical Carcinogenesis","volume":"21","author":"Tommasino","year":"2003","journal-title":"Hum Mutat"},{"key":"B293","article-title":"E7 Protein of Human Papilloma virus-16 Induces Degradation of Retinoblastoma Protein Through the Ubiquitin-Proteasome Pathway","volume":"56","author":"Boyer","year":"1996","journal-title":"Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.673699\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,11]],"date-time":"2021-05-11T06:39:00Z","timestamp":1620715140000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2021.673699\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,11]]},"references-count":293,"alternative-id":["10.3389\/fimmu.2021.673699"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2021.673699","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,11]]},"article-number":"673699"}}